Erudio Healtherudio.com
Clinical trial · no report yet · Early phase 1
NCT06318871 trial: what clinicians have said so far
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
- NCT06318871 ↗
- Active, not recruiting
- Dana-Farber Cancer Institute
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT06318871 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06318871 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
- Phase
- Early phase 1
- Status
- Active, not recruiting
- Conditions
- Renal Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Chromophobe Renal Cell Carcinoma; Translocation Renal Cell Carcinoma
- Interventions
- Cytokine Induced Memory-like Natural Killer (CIML NK) Cells; Interleukin-2 (IL-2)
- Arms
- Dose Level 0: CIML NK + low dose IL-2 · Experimental
- Dose Level -1: CIML NK + low dose IL-2 · Experimental
- Enrollment
- 5
- Primary outcomes
- Feasibility Failure Rate (FFR)
- Sponsor
- Dana-Farber Cancer Institute with Kidney Cancer Association
- Start
- Aug 28, 2024
- Primary completion
- Feb 28, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06318871 · updated Oct 23, 2026